[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346233-105":59,"doc-detail-346233-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","consent-concern-and-capacity-factors-associated-with-attitudes-toward-pharmacogenetic-testing-among-patients-with-gastrointestinal-cancer","Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer","","Pharmacogenetics (PGx) leverages drug-gene interactions to improve medication effectiveness and reduce toxicity. In gastrointestinal cancer care, PGx can inform chemotherapy dosing, yet routine pre-treatment testing remains limited by barriers, including limited evidence on counseling practices. This study evaluated genetics knowledge and PGx attitudes using a survey of Penn Medicine Biobank and IMPACT-GI participants, with multivariable modeling of patient characteristics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/consent-concern-and-capacity-factors-associated-with-attitudes-toward-pharmacogenetic-testing-among-patients-with-gastrointestinal-cancer/346233/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/consent-concern-and-capacity-factors-associated-with-attitudes-toward-pharmacogenetic-testing-among-patients-with-gastrointestinal-cancer/346233.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is pharmacogenetic (PGx) testing not routinely implemented for gastrointestinal cancer patients?","Question",{"text":112,"@type":113},"Pre-treatment PGx testing is limited by barriers, including insufficient data about counseling practices and related implementation challenges.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which factors were associated with greater willingness to undergo pharmacogenetic testing?",{"text":117,"@type":113},"Greater willingness was associated with higher genetics knowledge, being female, and higher self-reported health literacy.",{"name":119,"@type":110,"acceptedAnswer":120},"How did health insurance concerns affect patients’ attitudes toward PGx testing?",{"text":121,"@type":113},"Patients were less willing to undergo testing when they had health insurance concerns and when they did not complete secondary education.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346233,1791064379,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Clinical and Translational Science   \nConsent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer  \nArravinth Anantharajah1 | Raza Chaudhry2 | Victoria A. Wittner2  | Mari Angelica S. Cayabyab3  | Glenda Hoffecker3  | Xingmei Wang4 | Laura J. Conway2 | Penn Medicine Biobank5 | Ursina R. Teitelbaum1 | Sony Tuteja2   \n1Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA | 2Division of Translational Medicine and Human Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania,  \nUSA | 3Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA | 4Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA | 5Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA  \nCorrespondence: Sony Tuteja ([sony.tuteja@pennmedicine.upenn.edu](sony.tuteja@pennmedicine.upenn.edu))  \nReceived: 17 September 2025 | Revised: 24 November 2025 | Accepted: 10 December 2025  \nKeywords: DPYD | ethics | patient education | pharmacogenomics | return of results | UGT1A1  \nABSTRACT  \nPharmacogenetics (PGx) applies knowledge of drug-gene interactions to maximize effectiveness and reduce toxicity of medications. PGx impacts the dosing of chemotherapy for gastrointestinal cancer, including fluoropyrimidines and irinotecan. However, pretreatment PGx testing is not routinely implemented due to barriers, including insufficient data surrounding counseling practices. This study assessed genetics knowledge and PGx attitudes in patients with gastrointestinal cancers. A survey was distributed to Penn Medicine Biobank and IMPACT-GI participants. Multivariable analysis was conducted to assess the influence of genetics knowledge and patient characteristics on attitudes toward PGx. 132 participants completed the survey, 69 (52%) female, 22 (17%) non-White, 50 (38%) colorectal and 40 (30%) pancreatic cancers. The mean genetics knowledge score was 2.67 ± 1.14 correct responses out of 4. Willingness to undergo pharmacogenetic testing was associated with higher genetics knowledge (β = 0.6, 95% CI [0.1, 1.0], p = 0.0132), being female (β = 1.1, 95% CI [0.0, 2.2], p = 0.0435), and higher self-reported health literacy (β = 2.2, 95% CI [0.9, 3.5], p \u003C 0.001). Participants were less willing to undergo testing if they had health insurance concerns (β = −3.7, 95% CI [−5.8, −1.7], p \u003C 0.001) or did not complete secondary education (β = −2.0, 95% CI [−3.5, −0.6], p = 0.006) . Patients preferred providers to obtain consent and explain PGx's utility before testing. These findings provide initial patient-informed guidance for the implementation of pharmacogenetic testing in gastrointestinal cancer care and identify targets for patient education. As all survey respondents were research-engaged and from a single institution, the study population may not be widely generalizable.  \n1 | Introduction  \nGenetic variation accounts for anywhere from 20% to 95% of the differences in individual responses to medications, which can result in either a lack of efficacy or adverse drug reactions [1] . Pharmacogenetics (PGx) utilizes genetic information to  \noptimize medication prescribing and reduce the risk of toxicities, with the potential to significantly impact how medications are prescribed. PGx testing can be conducted using tumor or germline samples, but it is distinct from other specialized types of genetic testing targeted toward hereditary cancer risk or tumor molecular profiling. A total of 58  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commerci","cbCaitcrPDmLIHOm","https://ap.wps.com/l/cbCaitcrPDmLIHOm","pdf",271914,11,"English","# Abstract\n# Introduction\n# Study Highlights","[{\"question\":\"Why is pharmacogenetic (PGx) testing not routinely implemented for gastrointestinal cancer patients?\",\"answer\":\"Pre-treatment PGx testing is limited by barriers, including insufficient data about counseling practices and related implementation challenges.\"},{\"question\":\"Which factors were associated with greater willingness to undergo pharmacogenetic testing?\",\"answer\":\"Greater willingness was associated with higher genetics knowledge, being female, and higher self-reported health literacy.\"},{\"question\":\"How did health insurance concerns affect patients’ attitudes toward PGx testing?\",\"answer\":\"Patients were less willing to undergo testing when they had health insurance concerns and when they did not complete secondary education.\"}]","Consent, Concern, and Capacity: Factors Associated With Attitudes Toward Pharmacogenetic Testing Among Patients With Gastrointestinal Cancer | PDF",1790060568,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab71879250c7a6469b7b37613a64c318.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34c952f3e9542c0c3ca2efd35c0614b0.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3328e46f5f0e0534d9ad1d3fa0af29a.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6cd9b3ab19fc1d5bb78d3b1a2ee2f75.webp",980,1287]